首页> 美国卫生研究院文献>JCI Insight >SLC26A6-selective inhibitor identified in a small-molecule screen blocks fluid absorption in small intestine
【2h】

SLC26A6-selective inhibitor identified in a small-molecule screen blocks fluid absorption in small intestine

机译:SLC26A6选择抑制剂在小分子筛中鉴定在小肠中的液体吸收

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

SLC26A6 (also known as putative anion transporter 1 [PAT1]) is a Cl–/HCO3– exchanger expressed at the luminal membrane of enterocytes where it facilitates intestinal Cl– and fluid absorption. Here, high-throughput screening of 50,000 synthetic small molecules in cells expressing PAT1 and a halide-sensing fluorescent protein identified several classes of inhibitors. The most potent compound, the pyrazolo-pyrido-pyrimidinone PAT1inh-B01, fully inhibited PAT1-mediated anion exchange (IC50 ~350 nM), without inhibition of the related intestinal transporter SLC26A3 (also known as DRA). In closed midjejunal loops in mice, PAT1inh-B01 inhibited fluid absorption by 50%, which increased to >90% when coadministered with DRA inhibitor DRAinh-A270. In ileal loops, PAT1inh-B01 blocked fluid absorption by >80%, whereas DRAinh-A270 was without effect. In colonic loops, PAT1inh-B01 was without effect, whereas DRAinh-A270 completely blocked fluid absorption. In a loperamide constipation model, coadministration of PAT1inh-B01 with DRAinh-A270 increased stool output compared with DRAinh-A270 alone. These results provide functional evidence for complementary and region-specific roles of PAT1 and DRA in intestinal fluid absorption, with PAT1 as the predominant anion exchanger in mouse ileum. We believe that PAT1inh-B01 is a novel tool to study intestinal ion and fluid transport and perhaps a drug candidate for small intestinal hyposecretory disorders such as cystic fibrosis–related meconium ileus and distal intestinal obstruction syndrome.
机译:SLC26A6(也称为推定阴离子转运物1 [PAT1])是在肠细胞的腔膜上表达的CL- / HCO3-交换剂,其促进肠道和流体吸收。这里,在表达Pat1和卤素感测荧光蛋白的细胞中的50,000个合成小分子的高通量筛选鉴定了几种抑制剂。最有效的化合物,吡唑醇 - 吡啶嘧啶胺Pat1inH-B01,完全抑制Pat1介导的阴离子交换(IC50〜350nm),不抑制相关的肠传送器SLC26A3(也称为DRA)。在小鼠的闭合中间室环中,Pat1inh-B01抑制了50%的液体吸收,当与DRA抑制剂排水管A270共同进行时,增加至> 90%。在ILEAL环路中,PAT1INH-B01通过> 80%阻塞流体吸收,而排水管A270没有效果。在结肠环中,Pat1inH-B01没有效果,而排水管A270完全阻止流体吸收。在单替米德便秘模型中,与单独的排水管A270相比,PAT1INH-B01的共同分析PAT1INH-B01增加了粪便输出。这些结果提供了Pat1和DRA在肠道流体吸收中的互补和区域特异性作用的功能证据,PAT1作为小鼠回肠中的主要阴离子交换剂。我们认为,Pat1inh-B01是一种研究肠道离子和流体运输的新工具,也许是小肠乳糜蛋白疾病的药物候选者,如囊性纤维化相关的胎儿肝脏和远端肠梗阻综合征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号